Palvella Therapeutics (PVLA) Equity Average (2014 - 2026)

Palvella Therapeutics (PVLA) has 13 years of Equity Average data on file, last reported at $130.1 million in Q1 2026.

• Equity Average for Q1 2026 came in at $130.1 million, up 120.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $130.1 million (up 120.25% YoY), and the FY2025 annual result was $45.3 million, up 862.8% from the prior year.
• Equity Average climbed to $130.1 million in Q1 2026 per PVLA's latest filing, from $33.3 million in the prior quarter.
• Over five years, Equity Average peaked at $130.1 million in Q1 2026 and troughed at -$84.1 million in Q3 2024.
• A 5-year average of $11.3 million and a median of $33.3 million in 2025 frame the typical range for Equity Average.
• The sharpest annual moves came in 2024 and 2025: Equity Average slumped 381.83% in 2024, then soared 368.84% in 2025.
• A 5-year view of Equity Average shows it stood at $48.9 million in 2022, then sank by 144.96% to -$22.0 million in 2023, then surged by 43.61% to -$12.4 million in 2024, then soared by 368.84% to $33.3 million in 2025, then jumped by 290.45% to $130.1 million in 2026.
• Business Quant data shows PVLA's Equity Average at $130.1 million in Q1 2026, $33.3 million in Q4 2025, and $43.2 million in Q3 2025.